Frank Clyburn's most recent trade in Revolution Medicines Inc was a trade of 10,337 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Revolution Medicines Inc | Frank K. Clyburn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 10,337 | 10,337 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Frank K. Clyburn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 2,806 | 9,738 (0%) | 0% | 0 | Common Stock | |
| Cencora | Frank K. Clyburn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 789 | 1,157 (0%) | 0% | - | Common Stock | |
| Cencora | Frank K. Clyburn | Director | Grant, award, or other acquisition of securities at price $ 234.27 per share. | 01 Nov 2024 | 368 | 368 (0%) | 0% | 234.3 | 86,211 | Common Stock |
| Revolution Medicines Inc | Frank Clyburn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2024 | 27,744 | 27,744 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Frank K. Clyburn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2024 | 26,540 | 26,540 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Frank Clyburn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2024 | 6,932 | 6,932 (0%) | 0% | 0 | Common Stock | |
| IFF | Frank Clyburn | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 1,324 | 33,682 | - | - | Restricted Stock Units | |
| IFF | Frank Clyburn | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 1,324 | 2,170 (0%) | 0% | 0 | Common Stock | |
| IFF | Frank Clyburn | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.88 per share. | 01 Mar 2024 | 323 | 1,847 (0%) | 0% | 75.9 | 24,509 | Common Stock |
| IFF | Frank Clyburn | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 35,006 | 35,006 | - | - | Restricted Stock Units | |
| IFF | Frank Clyburn | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 1,323 | 5,296 | - | - | Restricted Deferred Stock Units | |
| IFF | Frank Clyburn | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 1,323 | 1,323 (0%) | 0% | 0 | Common Stock | |
| IFF | Frank Clyburn | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 91.64 per share. | 01 Mar 2023 | 477 | 846 (0%) | 0% | 91.6 | 43,712 | Common Stock |
| Merck & Company | Frank Clyburn | EVP & Pres ? Human Health | Sale of securities on an exchange or to another person at price $ 87.87 per share. | 30 Oct 2021 | 39,762 | 97,095 (0%) | 0% | 87.9 | 3,493,879 | Common Stock |
| Merck & Company | Frank Clyburn | EVP & Pres ? Human Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2021 | 19,915 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Frank Clyburn | EVP & Pres ? Human Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2021 | 19,915 | 117,010 (0%) | 0% | 0 | Common Stock | |
| Merck & Company | Frank Clyburn | EVP & Pres ? Human Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2021 | 19,847 | 19,848 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Frank Clyburn | EVP & Pres ? Human Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2021 | 19,847 | 136,857 (0%) | 0% | 0 | Common Stock | |
| Merck & Company | Frank Clyburn | EVP & Pres ? Human Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2021 | 2,358 | 0 | - | - | Restricted Stock Unit | |
| Merck & Company | Frank Clyburn | EVP & Pres ? Human Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.05 per share. | 30 Oct 2021 | 2,358 | 98,257 (0%) | 0% | 88.1 | 207,622 | Common Stock |
| Merck & Company | Frank Clyburn | EVP & Pres ? Human Health | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.05 per share. | 30 Oct 2021 | 1,162 | 97,095 (0%) | 0% | 88.0 | 102,314 | Common Stock |
| Merck & Company | Frank Clyburn | EVP & Pres ? Human Health | Sale of securities on an exchange or to another person at price $ 78.32 per share. | 10 May 2021 | 19,324 | 94,348 (0%) | 0% | 78.3 | 1,513,440 | Common Stock |
| Merck & Company | Frank Clyburn | EVP & Pres ? Human Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2021 | 19,324 | 19,323 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Frank Clyburn | EVP & Pres ? Human Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2021 | 19,324 | 113,672 (0%) | 0% | 0 | Common Stock | |
| Merck & Company | Frank Clyburn | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2021 | 131,633 | 131,633 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Frank Clyburn | EVP & Pres ? Human Health | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2021 | 39,479 | 39,479 | - | - | Restricted Stock Unit | |
| Merck & Company | Frank Clyburn | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 75.98 per share. | 04 May 2021 | 1,906 | 95,287 (0%) | 0% | 76.0 | 144,818 | Common Stock |
| Merck & Company | Frank Clyburn | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2021 | 1,906 | 0 | - | - | Restricted Stock Unit | |
| Merck & Company | Frank Clyburn | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.98 per share. | 04 May 2021 | 939 | 94,348 (0%) | 0% | 76.0 | 71,345 | Common Stock |
| Merck & Company | Frank Clyburn | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 72.62 per share. | 26 Feb 2021 | 9,432 | 92,588 (0%) | 0% | 72.6 | 684,952 | Common Stock |
| Merck & Company | Frank Clyburn | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2020 | 2,287 | 2,288 | - | - | Restricted Stock Unit | |
| Merck & Company | Frank Clyburn | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 75.89 per share. | 30 Oct 2020 | 2,287 | 83,655 (0%) | 0% | 75.9 | 173,560 | Common Stock |
| Merck & Company | Frank Clyburn | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.89 per share. | 30 Oct 2020 | 1,137 | 82,518 (0%) | 0% | 75.9 | 86,287 | Common Stock |